Effects of LiveSpo X-secret in Supporting Treatment of Sexually Transmitted Diseases

Not Applicable

Completed

• Conditions: Sexually Transmitted Diseases
• Interventions: Drug: 0.9% NaCl physiological saline; Combination Product: LiveSpo X-secret

• Registration Number: NCT05783856
• Lead Sponsor: Anabio R&D

Brief Summary

Sexually Transmitted Infections (STIs) are common gynecological infections worldwide, especially in tropical and underdeveloped countries, primarily affecting the reproductive age group. Microbial pathogens causing STIs include bacteria, viruses, fungi, and protozoa. In Vietnam, STIs are a significant public health concern due to their high incidence and tendency to have mild or no symptoms, making them easy to overlook. While antibiotics or antifungal drugs are typically used to treat STIs caused by bacterial or fungal agents such as Chlamydia, Gonorrhea, and Candida, no specific treatment exists for most viral STIs. Thus, vaccination and symptomatic treatment are the primary methods of prevention. The use of broad-spectrum antibiotics can result in side effects such as loss of appetite, fatigue, and sexual problems, while repeated treatments can lead to the emergence of antibiotic resistance, posing a significant challenge for STI treatment worldwide. However, the efficacy of oral or suppository-based probiotics is limited by their slow onset and sensitivity to acidic and temperature conditions. Fortunately, Bacillus strains of probiotics have demonstrated exceptional stability in both acidic and temperature environments, making them particularly well-suited for use as vaginal spray probiotics against STIs. Here, investigators propose that vaginal-spraying probiotics containing Bacillus strains could be a safe and effective symptomatic treatment for STIs caused by viral, fungi, or bacterial pathogens, providing a promising alternative to traditional antibiotic therapy.

The aim of the study about to evaluate the effectiveness of vaginal-spraying probiotics containing spores of three strains of Bacillus subtilis, Bacillus clausii, and Bacillus coagulans in preventing and supporting the treatment of vaginal infections.

Study Population: sample size is 100. The study is being carried out at Bac Ninh Center for Disease Control.

Description of Study Intervention: total of 100 eligible patients are divided randomly into 2 groups (n = 50/group): Patients in the Control group received routine treatment and 3 times/day 0.9% NaCl physiological saline while the patients in the experimental group were treated with LiveSpo X-secret 3 times/day in addition to the same standard of care treatment. The standard treatment regimen is 7 days and is maintained for 28 days.

Study duration: 36 months

Detailed Description

Sexually Transmitted Infections (STIs) are common gynecological infections worldwide, especially in tropical and underdeveloped countries where up to three-quarters of the population has STIs, mainly in the reproductive age. The infection rate in regions and countries is different, the infection rate in developing countries is 20-fold higher than in developed countries. Southeast Asia alone has about 150.5 million people with these diseases. Vietnam is located in the tropics, and hot and humid climates are favorable factors for microbial pathogens to develop. According to reports from the dermatology units of the provinces, every year about 300,000 people are infected with sexually transmitted diseases...There are many microbial pathogens causing infections including bacteria, viruses, fungi, and protozoa...The patient can be infected with multiple pathogens at the same time. This is a matter of great concern in public health care because STIs often have mild or no symptoms, so they are easily overlooked. While antibiotics or antifungal drugs are typically used to treat STIs caused by bacterial or fungal agents like Chlamydia, Gonorrhea, and Candida, no specific treatment exists for most viral STIs. However, the use of broad-spectrum antibiotics can result in side effects like loss of appetite, fatigue, and sexual problems, while repeated treatments can lead to the emergence of antibiotic resistance, posing a significant challenge for STI treatment worldwide. Probiotics are microorganisms that are beneficial to our health when consumed in adequate amounts, playing a vital role in maintaining a healthy balance of bacteria in our body, especially in the gut and vaginal areas. Studies have found that probiotics can help reduce the incidence and severity of vaginal infections, including bacterial vaginosis and yeast infections. Currently, oral or vaginal suppository probiotics containing strains of Bifidobacterium or Lactobacillus are being studied as a potential complementary therapy for treating vaginal infections. However, these strains have low survivability and are sensitive to light, moisture, and pH levels, making preservation challenging. Thus, their effectiveness depends on the specific strains used and the dose required to achieve colonization in the vaginal tract. Bacillus is a well-studied probiotic strain with over 350,000 research publications worldwide, and its safety has been extensively investigated. Bacillus subtilis, B. clausii, and B. coagulans are all aerobic or facultative anaerobic bacteria capable of spore formation and can tolerate harsh conditions such as nutrient deprivation, anoxia, drought, and even antibiotics. Here, investigators propose that vaginal-spraying probiotics containing Bacillus strains could be a safe and effective symptomatic treatment for STIs caused by viral, fungi, or bacterial pathogens, providing a promising alternative to traditional antibiotic therapy.

The objective was to investigate the symptomatic treatment effects of the probiotic product LiveSpo X-secret as a liquid-suspension form containing Bacillus spores of safe B. subtilis ANA4, B. clausii ANA39, B. coagulans ANA 40 strains, in women having sexually transmitted infection and investigators evaluation of improved efficacy and reduced clinical symptoms treatment time and measurement of changes in pathogen load in the vaginal samples before treatment (day 0) and after 3, 7, 14 and 28 days using LiveSpo X-secret.

Methods: A randomized, blind, and controlled clinical trial is conducted. After informed consent, patients will be screened for common nine STI pathogens in Vietnam including Gardnerella vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, Human alphaherpesvirus type 1 and 2, Candida albicans, Trichomonas vaginalis. Totally 100 patients positive with at least one of nine STIs will be randomized into 2 groups (n = 50/group): the control group (named "Control" group) uses 0.9% NaCl physiological saline and an experimental group (named the "X-secret" group) use the probiotics LiveSpo X-secret. The patient is given a coded spray in the form of a blind sample to ensure the objectivity of the study. The clinical follow-up will be at the time point of 0, 3, 7, 14, and 28 days, vaginal samples will be collected at days 0, 3, 7, 14, and day 28 to evaluate potential reductions in pathogens load and change the microbiome in vaginal flora.

Real-time PCR for detection of microorganism in vaginal samples: semi-quantitative assays for measuring changes in pathogens load is conducted by the real-time PCR assay which has been optimized and developed by the research team (Bui et al., 2023). Detection of useful Bacillus strains belonging to B. subtilis, B. clausii, and B. coagulans is conducted by real-time PCR SYBR Green assay that is routinely runs also conducted at Spobiotic Research Center, Hanoi, Vietnam

Analysis of vaginal microbiome 16S rRNA using next-generation sequencing (NGS) at Macrogene (Seoul, Korea) on the Illumina MiSeq (Illumina, San Diego, CA, USA) using a 2 × 250 bp run configuration.

During treatment, patients are monitored for typical clinical symptoms of gynecological infections, including itching, odor, vaginal color, and pH from vaginal samples of Control and X-secret groups at the time points of day 3, 7, 14, and day 28. The patients' health conditions are observed by doctors and nurses, and their pieces of information are filled into medical records at the patient's follow-up visits or phone interviews.

Data collection and statistical analysis: individual medical records are collected, and the patient's information is then gathered and systematized in a data set. The safety and efficacy of LiveSpo X-secret are evaluated and compared to 0.9% NaCl physiological saline based on the following clinical and sub-clinical criteria obtained in X-secret and Control groups: (i) the symptomatic-relieving day and level of symptom relief; (ii) the reduction levels (2\^△Ct) of pathogens load △Ct for target genes is calculated as Ct (threshold cycle) at day 3/7/14/28 - Ct at day 0 while Ct of internal control is adjusted to be equal among all samples; (iii) change the microbiome in vaginal flora.

The tabular analysis is performed on dichotomous variables using the χ2 test or Fisher's exact test when the expected value of any cell is below five. Continuous variables are compared using either the Wilcoxon test, t-test, or the Mann-Whitney test when data are not normally distributed. Statistical and graphical analyses are performed on GraphPad Prism v8.4.3 software (GraphPad Software, CA, USA). The significance level of all analyses is set at p \< 0.05. P-values.

Expected outcomes: (i) LiveSpo X-secret alleviates influenza-infection symptoms about 30% more effectively, as indicated by 90% of patients using LiveSpo X-secret (X-secret group) are symptom-free at day 3-28 of intervention depending on symptoms, compared to 60% of patients in Control group; (ii) Patients in X-secret group has more significant reductions in pathogens load (\>10 fold) than patients in Control group at the time point of day 3, 7, 14, 28 of intervention.

Study Timeline

• Study Start: 2020-05-03
• Study First Submitted: 2023-03-11
• Study First Submitted QC: 2023-03-23
• Study First Posted: 2023-03-24
• Primary Completion: 2023-03-31
• Study Completion: 2023-03-31
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-03
• Last Update Posted: 2023-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• Women aged from 18 to 60 years

• Amsel criteria for the diagnosis of vaginitis (presence of 3 of the following four criteria)

  • Increased uniform thin vaginal discharge;
  • pH of vaginal discharge greater than 4.5;
  • Vaginal odor;

• STI positive detected by multiplex real-time PCR TaqMan probe for nine major vaginal pathogens circulating in Vietnam. These include Gardnerella vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, Human alphaherpesvirus type 1 and 2, Candida albicans, Trichomonas vaginalis;

• Patients agree to participate in the study after a thorough explanation of the research is provided to them, and they sign the research consent form.

Read More

Exclusion Criteria

• Pregnant or nursing women, diabetics, taking antibiotics or antibiotics against vaginal infections in the previous 14 days.
• Unexplained vaginal bleeding or cancer.
• Having a history of drug allergies and hypersensitivity to any ingredient in probiotics or placebo.
• Discharged before day 7
• Meeting the criteria for psychiatric disorders other than depression and/or anxiety.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	0.9% NaCl physiological saline	Control group receives the routine treatment and uses 0.9% NaCl physiological saline. The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows: Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively. Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful.
X-secret	LiveSpo X-secret	X-secret group receives the routine treatment and uses NaCl 0.9% plus B. subtilis, B. clausii, and B. coagulans at 5 billion CFU/5 mL (LiveSpo®️ X-secret). The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows: Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively. Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful.

Primary Outcome Measures

Name	Time	Method
Percentage of patients with free and/or reduced gynecological infection symptoms	Day 0 to day 28	Percentage of patients with free gynecological infection including itching, odor, vaginal color, painful urination/ burning urine and lower abdominal pain; * Vaginal itching/ odor level (rating from 0 to 3 on a scale of: None-0, Mild-1, Severe-2, Very severe-3); * Colored vaginal discharge (Clear white-0, Opaque-1,Yellow/green-2, Gray white-3); * Painful urination/ burning urine (Yes/No); * Lower abdominal pain (Yes/No)

Secondary Outcome Measures

Name	Time	Method
Change the vaginal pH values	Day 0, 3, 7, 14, and day 28	Change the pH values of vaginal samples at day 3, day 7, day 14 and day 28 (after treatment) compared with day 0 (before treatment)
Change the vaginal flora	Day 0, 7, and day 28	Change the microbiome in vaginal flora, as indicated by the diversity of vaginal microbial species based on the data analysis of next-generation sequencing (NGS) at day 7 and day 28 (after treatment) compared with day 0 (before treatment)
Change the vaginal pathogens load	Day 0, 3, 7, 14, and day 28	Change the concentration of pathogens in vaginal samples, as indicated by real-time PCR threshold cycle (Ct) value at day 3, day 7, day 14 and day 28 (after treatment) compared with day 0 (before treatment)

Trial Locations

Locations (1)

Bac Ninh Center of Disease Control; 🇻🇳 Bac Ninh, Vietnam